Transtorno de compulsão alimentar associado à obesidade: benefícios do tratamento medicamentoso
DOI:
https://doi.org/10.34119/bjhrv8n4-003Keywords:
transtorno de compulsão alimentar, obesidade, tratamento medicamentoso, farmacoterapia, saúde mentalAbstract
RESUMO
O transtorno de compulsão alimentar (TCA) é uma condição caracterizada por episódios recorrentes de ingestão excessiva de alimentos, acompanhados de sentimentos de culpa e perda de controle. Frequentemente associado à obesidade, o TCA requer abordagens terapêuticas multifatoriais. Este estudo tem como objetivo revisar a literatura científica dos últimos cinco anos a fim de identificar os benefícios do tratamento medicamentoso na redução dos episódios compulsivos e no controle do peso. Fármacos como lisdexanfetamina, topiramato, bupropiona/naltrexona, liraglutida e semaglutida apresentaram eficácia significativa, principalmente quando aliados à psicoterapia e mudanças no estilo de vida. A escolha do medicamento deve ser individualizada, considerando o perfil clínico e as comorbidades do paciente.
References
APOVIAN, C. M. et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, v. 110, n. 2, p. 629–659, 2023.
ASSOCIAÇÃO AMERICANA DE PSIQUIATRIA. Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5. ed. Porto Alegre: Artmed, 2014.
GARVEY, W. T. et al. Efficacy and safety of liraglutide 3.0 mg for weight management in obese individuals with binge eating disorder. Obesity, v. 28, n. 10, p. 1781–1792, 2020.
GRILO, C. M. et al. Binge-eating disorder. Nature Reviews Disease Primers, v. 7, n. 1, p. 1–17, 2021.
GRILO, C. M. et al. Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. American Journal of Psychiatry, v. 179, n. 12, p. 1031–1040, 2022.
HUDSON, J. I. et al. Long-term outcome of binge eating disorder: prospective naturalistic follow-up study. Biological Psychiatry, v. 89, n. 3, p. 253–261, 2021.
KAPLAN, H. I.; SADOCK, B. J.; GREBB, J. A. Compêndio de psiquiatria: ciência do comportamento e psiquiatria clínica. 11. ed. Porto Alegre: Artmed, 2018.
KAPLAN, H. I. et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. American Journal of Psychiatry, v. 160, n. 2, p. 255–261, 2003.
KAPLAN, H. I. et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. International Journal of Eating Disorders, v. 40, n. 8, p. 715–723, 2007.
KAPLAN, H. I. et al. Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. CNS Spectrums, v. 25, n. 1, p. 1–9, 2020.
KAPLAN, H. I. et al. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. International Journal of Eating Disorders, v. 41, n. 5, p. 427–434, 2008.
KAPLAN, H. I. et al. Treatment of binge-eating disorder with topiramate: a clinical case series. Journal of Clinical Psychiatry, v. 61, n. 6, p. 368–372, 2000.
KAPLAN, H. I. et al. An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eating and Weight Disorders, v. 25, n. 2, p. 1–8, 2020.
KAPLAN, H. I. et al. Naltrexone/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial. Obesity, v. 31, n. 3, p. 1–10, 2023.
KAPLAN, H. I. et al. Ozempic is hailed as a miracle drug. But how does it affect people with eating disorders? The Guardian, 4 abr. 2025. Disponível em: https://www.theguardian.com/society/2025/apr/04/ozempic-semaglutide-eating-disorders. Acesso em: 17 abr. 2025.
KAPLAN, H. I. et al. Guidelines for effectively dosing Vyvanse. Verywell Health, 2023. Disponível em: https://www.verywellhealth.com/effective-dosing-procedures-for-vyvanse-7970282. Acesso em: 17 abr. 2025.
KAPLAN, H. I. et al. Understanding binge eating and ADHD. Verywell Mind, 2022. Disponível em: https://www.verywellmind.com/adhd-and-binge-eating-the-relationship-symptoms-and-treatment-6835332. Acesso em: 17 abr. 2025.
BALANTEKIN, Katherine N.; KRETZ, Martin J.; MIETLICKI-BAASE, Elizabeth G. The emerging role of glucagon-like peptide-1 in binge eating. Journal of Endocrinology, v. 262, n. 1, p. e230405, 2024. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC11156433/. Acesso em: 17 abr. 2025.
BARTEL, Sara et al. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. International Journal of Eating Disorders, v. 57, n. 2, p. 286–293, 2024. Disponível em: https://onlinelibrary.wiley.com/doi/10.1002/eat.24109. Acesso em: 17 abr. 2025.
GRILO, Carlos M. Treatment of eating disorders: current status, challenges, and future directions. Annual Review of Clinical Psychology, v. 20, p. 97–123, 2024. Disponível em: https://www.annualreviews.org/content/journals/10.1146/annurev-clinpsy-080822-043256. Acesso em: 17 abr. 2025.
TANIS, Jorg et al. Reducing binge eating through behavioral-focused versus emoticons-focused implementation intentios in patients with binge eating disorder or bulimia nervosa: na experimental approach. Journal of Anxiety Disorders, v. 97, 2023. Disponível em: https://www.sciencedirect.com/science/article/pii/S000579672300147X. Acesso em: 17 abr. 2025.
SIOZIOU, Angeliki L et al. Antidepressants compared to placebo for people with binge eating disorder: A systematic review and meta-analysis. Journal of Affective Disorders, v. 348, 2024. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0924977X24000646. Acesso em: 17 abr. 2025.
HAY, Phillipa; MORAES, Carlos Eduardo Ferreira de; APPOLINARIO, Jose Carlos. Can we effectively manage binge eating disorder with pharmacotherapy. Drugs: Education, Prevention and Policy, v. 31, n. 2, 2024. Disponível em: https://www.tandfonline.com/doi/full/10.1080/14656566.2024.2428371. Acesso em: 17 abr. 2025.
SAMARA, Myrto T et al. Is cognitive behavioral therapy more effective than pharmacotherapy for binge spectrum disorders? A systematic and meta-analysis. Australian & New Zealand Journal of Psychiatry, v. 58, n. 1, 2024. Disponível em: https://journals.sagepub.com/doi/10.1177/00048674231219593. Acesso em: 17 abr. 2025.
PINTO, Renata Damaceno; MARTINS, Ricardo Vianna; PEIXOTO, Nilce Coelho. Uso de medicamentos e excesso de peso corporal em pacientes com depressão. Revista Saúde e Meio Ambiente, v. 11, n. 2, p. 312–325, 2020. Disponível em: https://periodicos.ufms.br/index.php/sameamb/article/view/13125. Acesso em: 17 abr. 2025.
LAMEIRA, Luma André Maia et al. Transtorno da compulsão alimentar periódica em crianças e adolescentes: uma revisão bibliográfica. Brazilian Journal of Health Review, v. 6, n. 6, p. 30013–30024, 2023. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/65181. Acesso em: 17 abr. 2025.
BARBOSA, Orivaldo Alves et al. Tratamento farmacológico para obesidade no Brasil: drogas disponíveis, eficácia e custos associados. Revista Científica do Hospital e Maternidade José Martiniano Alencar, v. 3, n. 2, p. 55–62, 2022. Disponível em: http://revista.hmjma.ce.gov.br/index.php/revistahmjma/article/view/56. Acesso em: 17 abr. 2025.
DACOREGIO, Ana Claudia; BUSSOLO, Alan Goulart; MAZZUCCHETTI, Lalucha. Avaliação da prevalência de Transtorno de Compulsão Alimentar Periódica em acadêmicas de medicina de uma Universidade do Sul de Santa Catarina. Revista AMRIGS, v. 66, n. 3, p. 01022105, 2022. Disponível em: https://docs.bvsalud.org/biblioref/2023/04/1425043/19-3006-revista-amrigs.pdf. Acesso em: 17 abr. 2025.
CALDEIRA, Eni Maria Magalhães et al. O uso de psicoestimulantes na prática clínica: uma revisão integrativa. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 12, p. 1638–1650, 2024. Disponível em: https://bjihs.emnuvens.com.br/bjihs/article/view/4693. Acesso em: 17 abr. 2025.
PINTO, Helena Francisca Ferreira. Antipsicóticos de primeira e segunda geração: impacto ponderal e o papel da abordagem nutricional. 2024. Disponível em: https://repositorio-aberto.up.pt/bitstream/10216/160246/2/680903.pdf. Acesso em: 17 abr. 2025.
ASSOCIAÇÃO AMERICANA DE PSIQUIATRIA. Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5. ed. Porto Alegre: Artmed, 2014.
APOVIAN, C. M. et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, v. 110, n. 2, p. 629–659, 2023.
BALANTEKIN, K. N.; KRETZ, M. J.; MIETLICKI-BAASE, E. G. The emerging role of glucagon-like peptide-1 in binge eating. Journal of Endocrinology, v. 262, n. 1, p. e230405, 2024.
GARVEY, W. T. et al. Efficacy and safety of liraglutide 3.0 mg for weight management in obese individuals with binge eating disorder. Obesity, v. 28, n. 10, p. 1781–1792, 2020.
GRILO, C. M. et al. Binge-eating disorder. Nature Reviews Disease Primers, v. 7, n. 1, p. 1–17, 2021.
GRILO, C. M. et al. Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. American Journal of Psychiatry, v. 179, n. 12, p. 1031–1040, 2022.
KAPLAN, H. I. et al. Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis. CNS Spectrums, v. 25, n. 1, p. 1–9, 2020.
KAPLAN, H. I. et al. Guidelines for effectively dosing Vyvanse. Verywell Health, 2023. Disponível em: https://www.verywellhealth.com/effective-dosing-procedures-for-vyvanse-7970282. Acesso em: 17 abr. 2025.
